Phytochem Remedies (India) Limited is engaged in the manufacturing of corrugated boxes, sheets, rolls and packaging goods. The company earns revenue by supplying customized packaging solutions primarily to pharmaceuticals, agriculture, pesticides, FMCG and automotive sectors. Its products are used for storage, protection and transportation of goods. Revenue from operations stood at ₹3,653.62 lakh in FY25, growing at a CAGR of 32.46% from FY23 to FY25.

The Company is led by Promoter, i.e.,  ADITI BOHRA, BOHRA AGRIFILMS PRIVATE LIMITED, NIRANJAN SURANA AND SHILPA SURANA

The Revenues from operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 2,501.30 Lakh, ₹ 3,681.01 Lakh, â‚¹ 3,289.74 Lakh, and ₹ 2,082.57 Lakh, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 671.97 Lakh, ₹ 868.97 Lakh, ₹ 588.09 Lakh, and ₹ 291.24 Lakh, The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were â‚¹ 375.35 Lakh, ₹ 447.67 Lakh, â‚¹ 231.11 Lakh, and ₹ 81.89 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of â‚¹14.21 and post-issue EPS of ₹3.80 for FY25. The pre-issue P/E ratio is 6.90x,while the post-issue P/E ratio is 25.78x against the Industry P/E ratio is 17.76x The company's ROE for FY25 is 34.07% and RoNW is 34.07% The Annualised EPS is ₹6.38x and P/E is 15.37x. These metrics suggest that the IPO is Fully priced.

The Grey Market Premium (GMP) of Phytochem Remedies showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Phytochem Remedies Limited IPO for Listing gain or Long Term Purposes.